drugset / Trial / NCT06835465

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

NCT06835465

Phase 1 Completed 18 enrolled Genentech, Inc.
Non-randomizedCrossoverOpen-labelBasic science

Summary

This is a phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of rifampin on the pharmacokinetics (PK) and safety of divarasib in healthy participants.

Timeline

Start
2025-02-21
Primary completion
2025-05-06
Completion
2025-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Divarasib Small molecule Oral
Subject Rifampin Small molecule Oral

Indications

No indication recorded.